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Abstract
Background: We previously identified a 40 Mb region of linkage on chromosome 1q in our early
onset coronary artery disease (CAD) genome-wide linkage scan (GENECARD) with modest
evidence for linkage (n = 420, LOD 0.95). When the data are stratified by acute coronary syndrome
(ACS), this modest maximum in the overall group became a well-defined LOD peak (maximum
LOD of 2.17, D1S1589/D1S518). This peak overlaps a recently identified inflammatory biomarker
(MCP-1) linkage region from the Framingham Heart Study (maximum LOD of 4.27, D1S1589) and
a region of linkage to metabolic syndrome from the IRAS study (maximum LOD of 2.59, D1S1589/
D1S518). The overlap of genetic screens in independent data sets provides evidence for the
existence of a gene or genes for CAD in this region.
Methods: A peak-wide association screen (457 SNPs) was conducted of a region 1 LOD score
down from the peak marker (168–198 Mb) in a linkage peak for acute coronary syndrome (ACS)
on chromosome 1, within a family-based early onset coronary artery disease (CAD) sample
(GENECARD).
Results: Polymorphisms were identified within the 'family with sequence similarity 5, member C'
gene (FAM5C) that show genetic linkage to and are associated with myocardial infarction (MI) in
GENECARD. The association was confirmed in an independent CAD case-control sample
(CATHGEN) and strong association with MI was identified with single nucleotide polymorphisms
(SNPs) in the 3' end of FAM5C. FAM5C genotypes were also correlated with expression of the gene
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in human aorta. Expression levels of FAM5C decreased with increasing passage of proliferating
aortic smooth muscle cells (SMC) suggesting a role for this molecule in smooth muscle cell
proliferation and senescence.
Conclusion: These data implicate FAM5C alleles in the risk of myocardial infarction and suggest
further functional studies of FAM5C  are required to identify the gene's contribution to
atherosclerosis.
Background
Coronary artery disease (CAD), and its extreme manifes-
tation of myocardial infarction (MI), is the leading cause
of death in the United States [1] and, concomitant with
the epidemic of obesity and diabetes is rapidly becoming
the leading cause of death in many developing countries
[2]. The genetic predilection of CAD has been well-estab-
lished; family history has been repeatedly shown to be a
independent risk factor even after adjustment for shared
environmental factors [3,4]. The heritability of CAD is
particularly strong in early-onset forms of the disease (<
50 years of age) where the relative risk of developing early-
onset CAD in the first-degree sibling is between 3.8 and
12.1, depending on the age-of-onset in the proband [5].
Myocardial infarction, a serious manifestation of CAD,
has also been the subject of genetic analysis. In fact, the
only major successes in mapping genes for common,
complex cardiovascular disease have focused on the MI
phenotype, suggesting that this extreme (but common)
manifestation of CAD may be most powerful for disease
gene identification. For example, investigators in Iceland
carried out a genome wide linkage scan for MI in an Ice-
landic cohort [6]. Using fine-mapping techniques, the ara-
chidonate 5-lipoxygenase-activating protein (ALOX5AP)
gene was identified as the major susceptibility gene for MI
on chromosome 13q. Although initial results implicated
a single gene, expanded analysis of other leukotriene
pathway genes identified additional CAD/MI susceptibil-
ity genes [7]. Another study of MI revealed evidence for
linkage to chromosome 1p34 [8] and later identified
apolipoprotein E receptor 2 (LRP8) as an underlying sus-
ceptibility gene for familial and premature CAD and MI
[9]. Most recently, four CAD/MI genome wide association
studies (GWAS) [10-13] concomitantly identified genetic
association of a region on chromosome 9p21.3 adjacent
to the cyclin-dependent kinase inhibitor 2A (CDKN2A)
and cyclin-dependent kinase inhibitor 2B (CDKN2B)
genes within independent MI and CAD populations. A
study by Broadbent et al. validated these findings and
identified the antisense noncoding RNA in the INK4 locus
(ANRIL) as the potential disease-causing gene in this
region [14]. Despite these successes, these risk variants in
combination do not account for the entire underlying
genetic component of MI risk, suggesting further studies
to identify additional genetic risk factors are necessary.
We previously identified a 40 megabase region of linkage
on chromosome 1q25-31 in 420 families from our early
onset CAD genome-wide linkage scan (GENECARD) [15],
showing modest evidence for linkage (n = 420 families,
LOD 0.95). A priori stratification by sibling pairs concord-
ant for acute coronary syndrome (ACS; an extreme mani-
festation of CAD primarily composed of MI) revealed that
this modest maximum in the overall group became a well-
defined linkage peak (n = 228 families, LOD 2.17, at peak
microsatellite marker D1S1589/D1S518). This peak coin-
cides exactly with a quantitative trait locus (QTL) for
inflammatory biomarker (monocyte chemoattractant
protein 1, MCP-1) linkage in the Framingham Heart
Study (LOD 4.27, at peak marker D1S1589) [16], as well
as a linkage peak to metabolic syndrome (MetS) from the
IRAS family study (LOD 2.59, at peak marker D1S1589/
D1S518) [17]. MCP-1 is a potent inflammatory molecule
that promotes monocyte/macrophage accumulation in
atherosclerotic plaques, which can lead to plaque instabil-
ity through chronic inflammation and smooth muscle cell
proliferation [18]. Metabolic syndrome is a known strong
risk factor for development of CAD and MI [19-21]. The
overlap of genetic screens in independent data sets pro-
vides strong evidence for the existence of a susceptibility
gene or genes for CAD in this region.
We conducted a peak-wide association screen of 457 SNPs
across the region one LOD score down from the peak
marker (168–198 Mb) on chromosome 1q and identified
polymorphisms within the 'family with sequence similar-
ity 5, member C' (FAM5C) gene that show genetic linkage
to and are associated with MI. We confirmed association
within an independent CAD case-control dataset (CATH-
GEN) [22,23] and have identified strong association
between SNPs within the 3' end of FAM5C and myocar-
dial infarction. We show that FAM5C expression is corre-
lated with FAM5C genotype in human aortas, suggesting
that genetically heritable levels of this molecule in the
cells that make up the aorta may play a role in atheroscle-
rosis. Importantly, FAM5C is known to promote prolifer-
ation, migration, and invasion of pituitary tumors[24], a
phenotype relevant to the cellular changes of smooth
muscle cells that are associated with the formation and
vulnerability of an atherosclerotic plaque [25,26]. We
identified  FAM5C  expression in proliferating aortic
smooth muscle cells (AoSMCs) and show that levels ofBMC Medical Genetics 2008, 9:33 http://www.biomedcentral.com/1471-2350/9/33
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this molecule decrease with increasing passage, suggesting
that FAM5C levels may play a similar role in SMCs as in
pituitary cell tumors. We hypothesize that polymor-
phisms within this gene may alter FAM5C  levels in
smooth muscle cells, enhancing the atherosclerotic
smooth muscle cell phenotype, thus leading to plaque
instability and changes in MCP-1 levels.
Methods
Early-onset CAD family-based sample (GENECARD)
GENECARD is a collaborative study involving six interna-
tional investigative sites that make up the GENECARD
Study Network. The study is coordinated at Duke Univer-
sity. All study participants signed a consent form
approved by the responsible institutional review board or
local ethics committee. The study design has been previ-
ously reported [27]. Briefly, the initial genome-wide link-
age screen within the GENECARD study was composed of
493 affected sibling pairs in 420 families, where at least
two siblings met the criteria for early-onset CAD (eoCAD)
[15]. In order to obtain a more genetically homogenous
sample, using a priori defined analyses, our eoCAD sample
was stratified into acute coronary syndrome (ACS) fami-
lies. The presence of ACS was defined as diagnosis of myo-
cardial infarction or unstable angina in at least two
affected siblings (228 families) [15]. ACS is a serious man-
ifestation of CAD which includes the subgroup of MI, and
is diagnosed by the presence of at least two of the follow-
ing three signs/symptoms: chest pain typical of CAD,
changes on electrocardiogram, and/or positive serum
biomarkers for myocardial infarction (MI). Of the 985
affected individuals in the study, 697 met ACS criteria,
with 71 individuals with unstable angina only (89% with
MI). Given these data, and since MI and ACS represent
similar clinical phenotypes, for simplicity we consider the
ACS phenotype as primarily a myocardial infarction phe-
notype. In order to increase the power to detect associa-
tion in this sample, we included additional individuals
from the selected ACS families that were sampled after the
initial linkage screen was completed. A total of eight addi-
tional parents and 28 additional unaffected siblings were
added to the 228 ACS families. Furthermore, two addi-
tional families qualified for the ACS phenotype since the
original screen and were also included in the analysis. The
characteristics of the eoCAD (n = 420) and ACS (n = 230)
GENECARD families are summarized in Table 1.
MI case-control sample (CATHGEN)
CATHGEN participants were recruited sequentially
through the cardiac catheterization laboratories at Duke
University Hospital (Durham, North Carolina, United
States) with approval from the Duke Institutional Review
Board. All participants undergoing catheterization were
offered participation in the study and signed informed
consent. Medical history and clinical data were collected
and stored in the Duke Information System for Cardiovas-
cular Care database maintained at the Duke Clinical
Research Institute [28]. Controls and cases were chosen
on the basis of extent of CAD as measured by the CAD
index (CADi). CADi is a numerical summary of coronary
angiographic data that incorporates the extent and ana-
tomical distribution of coronary disease [29]. CADi has
Table 1: Clinical characteristics of samples used in this study
Variable eoCAD Probands ACS Probands MI Cases Controls Aorta Samples
(n = 422) (n = 228) (n = 368) (n = 289) (n = 88)
Age of onset (SD) 44.2 (5.8) 43.9 (6.1)† 51.5 (10.2)† 69.0 (7.0) exam 37.8 (13.2)
Race: Caucasian 92.9% 93%† 100%† 100.0% 87.9%
African American 2.1% 2.2% 0.0% 0.0% 8.6%
American Indian 4.0% 3.0% 0.0% 0.0% 0.0%
Asian 0.7% 0.9% 0.0% 0.0% 2.0%
Hispanic 0.0% 0.0% 0.0% 0.0% 3.5%
Other (unknown) 0.2% 0.4% 0.0% 0.0% 0.0%
Sex: Male 70.6% 72%† 83%† 43.0% 55.2%
Family history of CAD 100.0% 100%† 58%† 28.0%
Body Mass Index (SD) 29.9 (5.8) 29.9 (6.3) 29.9 (6.8) 28.2 (6.5)
Smoking 78.0% 84.0%† 72%† 39.0%
Diabetes 22.3% 22.0% 29.0% 15.0%
Hypertension 56.9% 57%† 66%† 66.0%
MI 65.9%* 89.0%*† 100%† 0.0% Data not available
Sys/Dias BP (SD) 140.1/84.0* (21.5/11.4) 140.6†/87.0* (22.0/12.0) 138.0†/74.0 (24.0/12.0) 149.0/76.0 (23.0/13.0)
Total Cholesterol (SD) 239.1 (64.8) 235.0† (67.0) 189.0† (56.0) 189.0 (43.0)
LDL (SD) 146.1 (54.3) 161.0† (125.0) 108† (42.0) 105.0 (35.0)
HDL (SD) 38.67 (16.3) 40.0 (14.0) 39.0 (12.0) 51.0 (19.0)
Triglycerides (SD) 230.1 (138.8) 221.0 (157.0) 226.0 (239.0) 169.0 (133.0)
*significant difference between eoCAD and ACS probands (p ? 0.05)
†significant difference between ACS probands and MI cases (p ? 0.05)BMC Medical Genetics 2008, 9:33 http://www.biomedcentral.com/1471-2350/9/33
Page 4 of 15
(page number not for citation purposes)
been shown to be a better predictor of clinical outcome
than extent of CAD [30]. Affected status was determined
by the presence of significant CAD defined as a CADi ? 32
[31], as we have used for previous studies [22,23]. For
patients older than 55 years of age, a higher CADi thresh-
old (CADi ? 74) was used to adjust for the higher baseline
extent of CAD in this group. Given the linkage to MI in the
GENECARD study, we also selected a subgroup of Cauca-
sian individuals who experienced MI from the overall
CATHGEN group, similar to the GENECARD ACS fami-
lies. MI was defined as documentation of MI in the medi-
cal history. Controls were defined as ?60 years of age, with
no CAD as demonstrated by coronary angiography and
no documented history of cerebrovascular or peripheral
vascular disease, myocardial infarction, transplant, or
interventional or surgical coronary revascularization pro-
cedures [32]. A comparison of clinical characteristics
between GENECARD probands and CATHGEN MI cases
and unaffected controls is presented in Table 1. As a repli-
cation data set, the CATHGEN sample provides 80%
power to detect effect sizes between 1.25 and 1.45, for
allele frequencies ranging from 0.1 to 0.5. The CATHGEN
MI cases were also stratified into a young affected group
(CAD AOO ? 55), which provides a consistent compari-
son for the GENECARD family study.
Human donor aorta samples and expression
Human aorta samples were collected from heart trans-
plant donors as previously described [33]. DNA and RNA
were isolated from each sample. Eighty-eight samples in
total were analyzed representing fifty-eight unique sam-
ples, as 30 individuals had more than one sample. As har-
vested tissue was obtained from deceased heart donors,
the clinical data associated with these aortas is very lim-
ited and consists of age, sex, and race (Table 1). Genotyp-
ing was performed using Applied Biosystems Taqman
allelic discrimination assays and expression profiling was
performed using Affymetrix GeneChip U95Av2 (Affyme-
trix, Santa Clara, CA). Expression signal intensity values
were log2 transformed and normalized using quantile nor-
malization. We analyzed cis effects of FAM5C variants on
FAM5C expression using the Affymetrix tag 34442_at, rep-
resenting the 3' end of FAM5C. Because some subjects had
multiple samples while others did not, we treated each
individual and sample separately. The expression level of
the tag was modeled using multiple linear regression
including age, sex, race and additive genotype. To account
for repeated measures (i.e., multiple sections per subjects)
and as a validation, a mixed model as implemented in the
SAS PROC MIXED procedure was utilized (SAS Institute
Inc., Cary, NC).
Peak-wide SNP selection
The approximate 30 Mb region of linkage on chromo-
some 1q contains 138 genes (NCBI Build 36 in Ensembl).
We used an iterative fine mapping approach that involved
selecting SNPs with a minor allele frequency of at least 5%
in the Caucasian population spaced at 100 kilobases (kb)
[34]. These SNPs were intercalated with at least one previ-
ously identified and confirmed (validated) SNP to repre-
sent positional candidate genes from NCBI Build 35 (120
genes). When possible, coding SNPs, SNPs that altered a
splice site or that were contained within putative regula-
tory regions of multi-species sequence conservation
(chimp, mouse, rat, dog, chicken, Fugu, zebrafish) were
selected for genotyping. If the gene was greater than 100
kb in size, multiple SNPs were selected using the same cri-
teria. Additionally, SNPs were selected from regions that
do not contain annotated genes at an average SNP to SNP
distance of 100 kb, while taking into account regions of
multi-species sequence conservation.
Using these criteria, 231 intragenic and 226 intergenic
SNPs were selected for genotype analysis within the chro-
mosome 1q linkage region with an average spacing of 66
kb. Twenty-seven genes contained validated coding SNPs
with allele frequencies >5%; twenty-two genes contained
synonymous SNPs with allele frequencies >5%; eleven
SNPs are found within untranslated regions (5' or 3'
UTR); and one hundred and seventy-one intronic SNPs
were selected, the reference allele is conserved within fifty-
five of these (Additional files, Table 1).
SNP genotyping
A total of 457 SNPs were genotyped at two genotyping
facilities. 384 SNPs were genotyped at the University of
Washington through a grant from SeattleSNPs (see Avail-
ability and requirements section for URL). Genotyping in
the GENECARD sample was performed by SeattleSNPs
using the Illumina BeadStation 500 G SNP genotyping
system (Illumina, San Diego, California, United States).
Each Sentrix Array generates 384 genotypes for 96 individ-
uals; within each individual array experiment, four sam-
ples purchased from Coriell were included as quality
control samples. The Coriell samples were of Centre
d'Etude du Polymorphisme Humain (CEPH) (Caucasian)
origin, Asian and Hispanic ethnicity and were used for
gender checking and to assess sample quality. In addition,
one sample per plate was duplicated for internal quality
control. These samples were used to identify possible sam-
ple plating errors and genotype calling inconsistencies.
Twenty-two SNPs did not cluster well and were not called.
The call rate for the remaining 362 SNPs was 99.8%. One
replicate error was identified in SNP rs2370025, all other
SNPs yielded greater than 99.999% concordance among
the replicates.
Ninety-five additional inter- and intragenic SNPs were
assayed at the Center for Human Genetics using Taqman
allelic discrimination assays. A total of 15 quality controlBMC Medical Genetics 2008, 9:33 http://www.biomedcentral.com/1471-2350/9/33
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samples – composed of six reference genotype controls in
duplicate, two CEPH pedigree individuals, and one no-
template sample – were included in each quadrant of the
384-well plate. SNPs that showed mismatches on quality-
control samples were reviewed by an independent geno-
typing supervisor for potential genotyping errors. All SNPs
examined were successfully genotyped for 95% or more of
the individuals in the study. Error rate estimates for SNPs
meeting the quality control benchmarks were determined
to be less than 0.2%.
Statistical analysis
All SNPs were tested for deviations (p ? 0.0001) from
Hardy-Weinberg equilibrium (HWE) in the affected and
unaffected race-stratified groups. Two SNPs deviated from
HWE in the peak-wide association study, rs1503122
(cases) and rs438781 (cases and controls). Neither of
these SNPs was statistically significant in our association
analysis. Interestingly, rs438781 lies within a reported
copy number polymorphism, which is most likely the
cause of the disequilibrium. In CATHGEN, one SNP,
rs9427746, significantly deviated from HWE (p < 0.0001)
in the Caucasian control group. This deviation was neither
due to mixed racial backgrounds as all of the samples were
from Caucasian origin, nor was it due to assay dropout as
all of our controls are randomly interspersed with our
cases in the 384 well plates. This deviation is either a sig-
nificant departure representing an association or due to
random chance. Linkage disequilibrium between pairs of
SNPs was assessed using the Graphical Overview of Link-
age Disequilibrium package [35] and displayed using
Haploview [36].
In the initial screen, two-point linkage using a dominant
and recessive model was performed using Fastlink [37,38]
and Homog [39] and family-based association was tested
using the Association in the Presence of Linkage (APL) test
[40]. We analyzed the GENECARD families together
regardless of race because these families formed the basis
of the original linkage evidence. We chose to use the APL
test for family based association because this test incorpo-
rates data from affected sibling pairs with available paren-
tal data and unaffected siblings in the analyses, effectively
using all available information in the GENECARD fami-
lies. The APL software infers missing parental genotypes,
appropriately accounts for the non-independence of
affected siblings and calculates a robust estimate of the
variance. APL results from markers with variance esti-
mates of less than five are viewed as less reliable [41]. A
single SNP in TROVE2  was significant in our original
screen with a variance less than five and did not replicate.
In addition to APL, family-based association of FAM5C
SNPs was performed using the Pedigree Disequilibrium
Test (PDT) [42,43]. We employed this additional test at
the gene level in order to obtain the most information
about each polymorphism. The PDT test uses related trios
and discordant sibships from extended pedigrees and like
other family-based association tests is robust to popula-
tion stratification. In order to determine if replicated SNPs
could account for the MI linkage signal we employed
Linkage and Association Modeling in Pedigrees (LAMP).
LAMP estimates the degree of linkage disequilibrium (LD)
between a candidate SNP and the putative disease locus
through joint modeling of linkage and association
[44,45].
Allelic association in the CATHGEN MI cases and controls
was evaluated using multivariable logistic regression
modeling adjusted for sex, and known CAD risk factors
(history of hypertension, history of diabetes mellitus,
body mass index, history of dyslipidemia, and smoking
history) as covariates. These adjustments could hypothet-
ically allow us to control for competing genetic pathways
that are independent risk factors for CAD, thereby allow-
ing us to detect a separate CAD genetic effect. SAS 9.1 (SAS
Institute, Cary, North Carolina, United States) was used
for statistical analysis.
FAM5C sequencing
To identify novel SNPs within seven regions of multi-spe-
cies sequence conservation localized to the last intron of
FAM5C  (see Additional files, Figure 1, arrows), PCR
amplicons were generated using standard conditions and
sequenced using ABI Big Dye v3.1 and an ABI 3730 auto-
mated sequencer (primers available upon request).
Sequencing data were analyzed using Sequencher soft-
ware (GeneCodes, Ann Arbor, Michigan, United States).
All amplicons were generated within 16 affected and 16
unaffected GENECARD individuals (16 Caucasian males
and 16 Caucasian females). Primer sets for each region are
listed in Additional files, Table 2.
Aortic endothelial and smooth muscle cell culture
Cryopreserved human aortic smooth muscle (AoSMC)
and human aortic endothelial cells (HAEC) were
obtained from Lonza (Walkersville, MD) at passage 3 and
cultured using SGM-2 or EGM-2 media (Lonza) until the
indicated passage. Cells were grown in T-75 SoLo Flasks
Nunclon™? (NUNC, Rochester, NY) according to manu-
facturer's instructions (see Availability and requirements
section for URL).
Reverse transcriptase PCR (RT-PCR)
RNA from 20 human tissues (Human Total RNA Master
Panel II) was obtained from Clontech (Mountain View,
CA). Lot number 6020107 contained RNA from the fol-
lowing tissue types: Fetal Brain, Spinal Cord, Skeletal
Muscle, Lung, Trachea, Fetal Liver, Liver, Bone Marrow,
Kidney, Thymus, Thyroid, Adrenal Gland, Salivary Gland, BMC Medical Genetics 2008, 9:33 http://www.biomedcentral.com/1471-2350/9/33
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Table 2: LAMP Analysis in GENECARD ACS families and replication in CATHGEN MI cases and controls
SNP LOCATION 
(bp)
Alleles LINKAGE TEST 
(df = 3)
ASSOCIATION 
TEST (df = 1)
OTHER LINKED 
VARIANTS (df = 2)
CATHGEN MI Logistic regression† CATHGEN Minor 
Allele Frequency
Major Minor LOD pvalue LOD pvalue LOD pvalue Allele pvalue Allele OR (95% CI)*
RS7514392 188,323,178 C g 2.95 0.004 0.33 0.220 1.69 0.020 - - -
RS10920501 188,328,568 A t 2.98 0.003 0.96 0.040 2.27 0.005 0.018 0.612 (0.408–0.919) 0.18
RS12142564 188,338,626 C t 2.80 0.005 1.43 0.010 2.53 0.003 0.322 0.799 (0.508–1.257) 0.11
RS2185836 188,349,217 A g 2.89 0.004 0.76 0.060 2.82 0.002 0.273 0.791 (0.521–1.202) 0.45
RS2419370 188,375,504 T c 2.50 0.009 0.56 0.110 2.49 0.003 0.003 1.925 (1.251–2.961) 0.44
RS2990996 188,411,850 C a 3.19 0.002 0.16 0.400 3.18 0.001 0.115 1.441 (0.915–2.271) 0.50
RS815343 188,422,256 C t 2.97 0.003 0.34 0.210 2.31 0.005 0.005 0.574 (0.392–0.842) 0.39
RS1891586 188,430,617 T g 2.95 0.004 0.04 0.700 2.93 0.001 0.003 0.563 (0.385–0.823) 0.23
RS9427746 188,438,263 G c 2.86 0.004 0.01 0.810 2.50 0.003 0.007 0.587 (0.399–0.863) 0.40
RS10920678 188,506,530 G a 2.99 0.003 0.01 0.850 2.77 0.002 0.159 0.753 (0.508–1.117) 0.43
RS480692 188,526,284 T c 3.29 0.002 0.41 0.200 3.42 0.000 0.028 1.591 (1.052–2.405) 0.43
RS12724000 188,618,300 C t 2.78 0.005 0.04 0.660 2.60 0.003 0.031 0.645 (0.434–0.961) 0.17
RS872177 188,659,068 T a 2.93 0.004 0.05 0.600 2.90 0.001 0.188 0.776 (0.533–1.132) 0.31
RS2134098 188,660,894 G c 2.82 0.005 0.89 0.040 3.00 0.001 0.131 0.679 (0.411–1.122) 0.08
RS10920722 188,694,717 A t 2.65 0.007 0.07 0.600 2.37 0.004 0.009 0.589 (0.397–0.874) 0.19
RS10920725 188,707,160 T c 2.65 0.007 0.13 0.400 2.45 0.004 0.007 0.584 (0.394–0.865) 0.20
RS11581737 188,726,896 G a 2.87 0.004 0.18 0.400 2.76 0.002 0.031 0.642 (0.429–0.960) 0.16
*Odds Ratio (OR) calculated for minor allele, - not tested
†adjusted for sex, history of hypertension, history of diabetes mellitus, body mass index, history of dyslipidemia, and smoking history
Chromosome 1 peak-wide mapping of genes involved in myocardial infarction Figure 1
Chromosome 1 peak-wide mapping of genes involved in myocardial infarction. 457 SNPs were genotyped across 
the 1 LOD down region of linkage on chromosome 1 in the GENECARD ACS sample. Association was assessed using APL. 
The -log10 of the p-value is plotted according to chromosome position (closed circles). Markers with a p-value less than 0.05 fall 
above the dashed line; labels identify these genes and intergenic SNPs. Markers in bold exhibited modest evidence for linkage 
(LOD ? 1) in two point analysis. Sixteen markers that were associated (p ? 0.05) in the GENECARD ACS sample were geno-
typed in a MI case-control population (open circles). Markers which show replication are underlined.BMC Medical Genetics 2008, 9:33 http://www.biomedcentral.com/1471-2350/9/33
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Uterus, Testes, Prostate, and Placenta. RNA from cultured
aortic smooth muscle and endothelial cells was isolated
using a Ribopure Kit from Applied Biosystems (Foster
City, CA). cDNA was synthesized using the protocol for
cDNA synthesis in the Illumina Total Prep RNA Amplifi-
cation kit from Applied Biosystems (Foster City, CA).
Primers corresponding to exon 6 and exon 7 of FAM5C
were used for PCR from cDNA (5'-ACAACAGTGACTTT-
GAGGAATCAGA-3' and 5'-GCGCTGAAAATTAGAATC-
CATTG-3'). Primers corresponding to exons 8 and 9 of
GAPDH were used as a template control (5'-CTCCTCCAC-
CTTTGACGCTG-3', and 5'-AGGGGAGATTCAGTGT-
GGTG-3'). 20 ng of cDNA template was used for each
reaction and Platinum Taq polymerase (Invitrogen,
Carlsbad, CA) was used for all PCR reactions. PCR reac-
tion conditions were as follows: Step 1: 95°C for 5 min-
utes, Step 2: 30 cycles (FAM5C) or 20 cycles (GAPDH) of
95°C for 1 minute followed by 62°C for 1 minute, and
72°C for 1 min, and Step 3, 72°C 10 min.
FAM5C real time RT-PCR
Applied Biosystems Taqman Gene expression assays were
used to perform quantitative (real time) RT-PCR (FAM5C,
Hs00982332_m1 and GAPDH, Hs02758991_g1). The
following reaction components were used for each probe:
2 uL cDNA, 5 ul Custom TaqMan SNP Master Mix
(Applied Biosystems, Foster City, CA), 0.5 ul of assay, and
2.5 ul water. Reactions were performed in a single 384
well plate in triplicate using an ABI PRISM® 7900 HT
Sequence Detection System. PCR reaction conditions
were as follows: Step 1: 50°C for 2 minutes, Step 2: 95°C
for 10 minutes, Step 3: 40 cycles of 95°C for 15 seconds
followed by 60°C for 1 minute. Expression relative to
GAPDH was calculated using 2?Ct [46] and levels were nor-
malized to heart expression.
Results
Peak-wide genotyping and analysis in GENECARD ACS 
linkage Peak
457 SNPs, at an average spacing of 66 kilobases, were gen-
otyped in the one LOD down support interval (169–199
Mb) of the GENECARD chromosome 1q ACS linkage
peak (see Additional files, Table 1). Family-based associa-
tion performed in the ACS families using APL identified
sixteen SNPs that were significant at p ? 0.05 (Figure 1,
Additional files, Table 3), three of which also displayed
linkage: rs10912660 in the ankyrin repeat domain 45
gene (ANKRD45), rs12092963 in the ral guanine nucle-
otide dissociation gene (RGL1), and rs1891586 in FAM5C
(Figure 1, bold). The clinical characteristics comparing the
ACS probands in GENECARD to the MI cases in CATH-
GEN show the suitability of this group for replication
(Table 1). Three of the sixteen SNPs replicated in the
CATHGEN MI cohort at p ? 0.05 (Figure 1, underlined).
Two SNPs, rs2239816 and rs1891586, reside within
genes, chromosome 1 open reading frame 9 protein
(C1orf9) and FAM5C, and the third within an intergenic
region (rs1324713).
A SNP found within the first intron of the tumor necrosis
factor superfamily 4 gene (TNFSF4), rs3850641, residing
within the chromosome 1q linkage peak, has previously
shown to be associated with MI in two independent pop-
ulations [47], but although it was linked, was not associ-
ated in the GENECARD samples (Additional files, Table
4). LAMP analysis determined that this SNP does not
account for the linkage observed in these families (data
not shown).
tagSNP genotyping and analysis
We chose haplotype tagging SNPs in C1orf9, FAM5C and
the intergenic region 100 kilobases upstream and down-
stream of rs1324713. None of the additional genotyped
tagSNPs in C1orf9 or the intergenic region displayed both
association and linkage (Additional files, Table 4). How-
ever, the original C1orf9  SNP identified in the screen,
rs2239816, is significantly associated in both GENECARD
ACS (APL, p = 0.05) and CATHGEN MI samples (allele p
= 0.04) and results in an amino acid change at position 11
(Pro11Ser). This SNP does not, however, explain the link-
age seen in our ACS family subset.
A single SNP in FAM5C (rs1891586) from the peak-wide
screen showed both linkage and association in the ACS
sample (maximum LOD = 1.54, p = 0.027). To further
fine map the gene we selected 67 haplotype tagging SNPs
using HapMap data and Tagger [48] (capturing 100% of
the alleles at r2 = 0.8 in the European population) from a
region that spanned FAM5C and 15 kilobases upstream
and 5 kilobases downstream of the gene. Only 48 of these
SNPs had minor allele frequencies >5% and were inform-
ative given the small sample size when genotyped in the
GENECARD ACS families. Sixteen of these SNPs dis-
played linkage (LOD ? 1 in either model) and/or associa-
tion (p ? 0.05) (Figure 2, Figure 3, Additional files, Table
5), with three SNPs (rs2134098, rs12142564 and
rs10920501) partially accounting for the linkage signal on
chromosome 1 (Table 2, compare association test to other
linked variants) by LAMP analysis [44,45]. In the CATH-
GEN sample, twelve of these sixteen SNPs were signifi-
cantly associated with MI (Table 2), however, only one of
the three SNPs that partially accounted for linkage in
GENECARD (rs10920501) was associated with MI in
CATHGEN. Interestingly, when we stratified our MI sam-
ple by age of onset (see methods), we found that the
strength of the overall rs10920501 signal increased within
the young affected group (T allele, p = 0.009, OR = 0.539).
This SNP tags (r2 ? 0.8) 6 additional SNPs that flank the
last exon on FAM5C (see Addition files, Figure 1). This BMC Medical Genetics 2008, 9:33 http://www.biomedcentral.com/1471-2350/9/33
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FAM5C tagSNPs are associated and linked to acute coronary syndrome Figure 2
FAM5C tagSNPs are associated and linked to acute coronary syndrome. 47 haplotype tagging SNPs were selected to 
span the length of FAM5C as well as 15 kb up and 5 kb downstream of the gene to account for potential regulatory elements. 
Parametric linkage (A), APL association (B) and PDT association (C) were assessed. SNPs that were linked (LOD ? 1) and/or 
associated (p ? 0.05) were selected for replication (markers that fall above the dashed lines, n = 16). * denotes rs10920501.BMC Medical Genetics 2008, 9:33 http://www.biomedcentral.com/1471-2350/9/33
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SNP is in linkage equilibrium (r2 = 0.04) with rs1891586,
the original SNP identified in the peakwide screen.
Sequencing FAM5C conserved regions in intron 7
We noted blocks of multi-species sequence conservation
in the last intron of FAM5C and hypothesized that the
causal SNP, in LD with rs10920501, may lie in one of
these regions. The allele frequency of rs10920501 is
approximately 16% in the Caucasian population. We
rationalized that a causal SNP that was in LD with
rs10920501 would be at a similar allele frequency. Given
Kruglyak and Nickerson's estimates [49] we performed
sequencing across 32 individuals that should allow for a
SNP detection rate between 99% and 99.9% at a minor
allele frequency of 10%. The seven conserved regions (see
Additional files, Figure 1, arrows) were PCR amplified
from 16 Caucasian cases and 16 Caucasian controls using
standard conditions and sequenced. No novel SNPs were
identified (data not shown).
FAM5C allele specific gene expression
We next asked if rs10920501 (or an unidentified SNP in
linkage disequilibrium with rs10920501) was function-
ally relevant to CAD. We genotyped a set of aorta samples
that we had previously collected for expression analysis
[33] and we found that the inheritance of the T allele of
rs10920501 is significantly associated with a reduction in
the expression of FAM5C in aorta (Figure 4) (p = 0.03 in
generalized model; p = 0.02 in mixed regression model to
account for repeated measures). Since the T allele is pro-
tective in our sample (allelic odds ratio, 0.609 in CATH-
GEN, Table 2) and carriers of the T allele show decreased
FAM5C gene expression in aorta, higher expression of
FAM5C in the cells that make up the artery may be related
to increased risk of MI. Because a QTL for MCP-1 in the
Framingham Heart Study overlaps with the GENECARD
ACS linkage peak, we also tested the effect of rs10920501
on MCP-1 expression levels in the aorta, but found no evi-
dence for any relationship (data not shown).
Schematic of FAM5C gene structure and pairwise LD between FAM5C SNPs Figure 3
Schematic of FAM5C gene structure and pairwise LD between FAM5C SNPs. (A) Sixteen of forty-seven tagSNPs in 
FAM5C that were tested for replication and linkage are shown. SNPs with an open arrow are found outside of the gene. All 
sixteen SNPs represent 16 of 47 linkage disequilibrium (LD) blocks. (B) LD was estimated in one unaffected Caucasian individ-
ual from each non-redundant GENECARD ACS sibling pair. A similar pattern of LD was observed using the CATHGEN MI 
affected and unaffected individuals.BMC Medical Genetics 2008, 9:33 http://www.biomedcentral.com/1471-2350/9/33
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FAM5C is expressed in proliferating human aortic smooth 
muscle cells and expression changes with passage
Given that FAM5C is expressed in human aorta, we sought
to determine if FAM5C is expressed in smooth muscle and
endothelial cells, the primary constituents of the human
aorta. We cultured proliferating aortic smooth muscle
(AoSMC) and human aortic endothelial cells (HAEC) and
isolated RNA. Reverse transcriptase PCR (RT-PCR) identi-
fied  FAM5C  expression in both endothelial and aortic
smooth muscle cells (Figure 5A, lanes 2, 3, and 4). In
order to determine if FAM5C expression was specific to
the brain and arteries, we assayed expression of FAM5C in
20 human tissues and found that it is expressed in many
different tissue types at varying levels (Additional files,
Figure 2).
We noted that the expression levels of FAM5C appeared to
vary with AoSMC passage (compare p.5 and p.8 AoSMC
FAM5C expression is modulated by the T allele of rs10920501 Figure 4
FAM5C expression is modulated by the T allele of rs10920501. Eighty-eight human donor aorta were harvested, gen-
otyped for rs10920501, and assayed for FAM5C expression using Affy tag 34442_at. Box plots are shown for gene expression 
by genotype. The presence of the T allele of rs10920501 significantly reduces FAM5C expression. The p-value shown is for the 
generalized model adjusted for age, sex, and race. * n = 1 in the TT genotype group.BMC Medical Genetics 2008, 9:33 http://www.biomedcentral.com/1471-2350/9/33
Page 11 of 15
(page number not for citation purposes)
RT-PCR Figure 5 and Additional files, Figure 2) and there-
fore hypothesized that FAM5C levels may change with
proliferative capacity and cellular senescence. Sub-cultur-
ing of primary cells, such as AoSMC, results in a progres-
sive reduction of proliferation until the cells reach
senescence, described as Hayflick's limit [50]. We serially
cultured AoSMC derived from a 29 year old Caucasian
male donor until senescence (passage 20) indicated by
cessation of proliferation and an enlarged flattened cell
morphology. We measured the level of FAM5C expression
in triplicate during each passage (passage 8 RNA was
depleted) using real time RT-PCR. We found that FAM5C
levels decrease as cells age in culture (Figure 5B).
FAM5C is expressed in aortic endothelial and smooth muscle cells Figure 5
FAM5C is expressed in aortic endothelial and smooth muscle cells. (A) RT-PCR was performed on RNA derived from 
the cerebellum (control) and proliferating aortic endothelial (HAEC, passage 6) and smooth muscle cells (AoSMC, passage 5 
and 8). (B) Real time RT-PCR was performed on RNA isolated from serially passed AoSMC. Aliquots were taken at every pas-
sage and experiments were performed in triplicate. FAM5C and GAPDH expression were assayed at the same time and GAPDH 
was used to normalize all samples. The expression level was calculated relative to heart RNA (control). Standard deviation was 
calculated for each experiment and is indicated by grey bars.BMC Medical Genetics 2008, 9:33 http://www.biomedcentral.com/1471-2350/9/33
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Discussion and Conclusion
We herein report the results of fine-mapping a linkage
peak for MI and identifying a novel MI susceptibility gene,
FAM5C. We show that polymorphisms in FAM5C  are
associated with MI in two independent samples and that
the SNP, which partially accounts for the linkage in our
GENECARD ACS peak, is also significantly associated
with changes in FAM5C gene expression in the human
aorta. To begin to address the functional role of FAM5C in
MI, we observed that FAM5C is expressed in the human
aorta and that its transcript levels decrease with increasing
passage of AoSMC, suggesting that the level of gene
expression may play a role in proliferation and senescence
of this cell type.
FAM5C was originally identified in the mouse brain as a
gene that is induced by bone morphogenic protein and
retinoic acid signaling (BRINP3  gene) [51] and has
recently been shown to be over-expressed in human pitu-
itary tumors [24]. In the aforementioned study, the
authors show that FAM5C is localized to the mitochon-
dria and that over-expression of this molecule leads to
increased proliferation, migration, and invasion of non-
tumorogenic pituitary cells (the opposite being true for
knockdown of FAM5C). Through complex signaling cas-
cades, mitochondria have the ability to activate multiple
pathways that modulate both cell proliferation and, con-
versely, promote cell arrest and programmed cell death
(reviewed in [52,53]). FAM5C localization to the mito-
chondria and its putative role in regulating cell prolifera-
tion and migration provide an intriguing hypothesis for
the role of FAM5C in smooth muscle cells and the forma-
tion and vulnerability of the atherosclerotic plaque. SMCs
move from a contractile state to a proliferative, migratory
state in the presence of endothelial cell dysfunction at the
initiation phase of plaque formation. They migrate into
the region of plaque formation and form the fibrous cap
that covers the plaque which is prone to rupture (reviewed
in [25]). FAM5C levels could play a role in the initiation
of smooth muscle cell proliferation and migration and/or
in the disintegration of the smooth muscle cell in the
fibrous cap. We are currently conducting experiments to
determine if FAM5C levels have effects on smooth muscle
cell proliferation, migration, apoptosis and senescence.
While our analysis was primarily aimed at an MI pheno-
type, our ACS family sample included a limited number of
individuals with unstable angina. As a result the power to
detect a distinct MI effect may be somewhat lower in our
ACS family data set. Nevertheless, we observed consistent
and replicated results in the MI case-control set and in the
ACS family data set, suggesting that our results are robust
to potential phenotypic heterogeneity. In addition, two
recent WGA studies from the Framingham Heart Study
have identified significant association between atrial
fibrillation (AF) and FAM5C (rs1604355), and also for
left atrial size (LAS) and FAM5C  (rs1935881) [54,55].
Both of these SNPs are in low LD (r2 < 0.1) with
rs10920501; however, a SNP within the linkage disequi-
librium bin containing rs10920501 was not represented
on the SNP chip used in these studies, leaving open the
possibility that rs10920501 may also play a role in these
phenotypes. Although atrial fibrillation and left atrial size
are very different phenotypes from MI, these data,
together with the data presented in this paper, suggest that
further genetic and functional studies are warranted to
determine the role of FAM5C and variation within this
gene in diverse diseases in cardiovascular tissues.
Three separate studies identified linkage to the same
region of chromosome 1, the Framingham Heart Study
[16], the IRAS family study [17], and the GENECARD
study [15]. Through careful fine mapping of a linkage
peak for an extreme CAD phenotype, MI, we have defined
a single gene that can partially account for the linkage in
this peak. The relationship between MCP-1 levels, meta-
bolic syndrome, MI, and FAM5C still remains to be
defined. Inflammation lies at the heart of these patho-
physiologies. We know that inflammation is an important
part of metabolic syndrome [56], individuals with meta-
bolic syndrome are at higher coronary disease risk [57],
and metabolic syndrome increases the risk of an event
(MI, revascularization, or cardiac death) in individuals
with a family history of MI [58]. In addition, vascular
SMC pathophysiology is related to inflammation which
could explain the MCP-1 QTL linkage. Further work is
clearly indicated in this area.
One of the more difficult aspects of genetic association
analysis is how to appropriately correct for multiple com-
parisons in evaluating the statistical significance of any
given result. Possible approaches range from the most
conservative Bonferroni correction, to estimation of false
discovery rate [59], to weighted corrections of combined
data, to no correction at all. We are aware that the p-values
presented in this paper were not corrected for multiple
comparisons. Our enthusiasm for FAM5C as an MI sus-
ceptibility gene is based on the observed replication of
association results from multiple independent data sets
and different approaches. The line of reasoning has sev-
eral parts. First, rs10920501 represents a significant
marker that can partially account for the linkage signal in
our ACS families, and the statistical significance of the
observation replicates in an independent case-control
sample. Second, the probability of observing three or
more significant results out of sixteen in the independent
case-control sample under the null hypothesis that there
is no association (p ? 0.05) is 0.043. Third, we have
observed that the level of the transcript in the aorta is asso-
ciated with genetic variation this SNP (or a SNP LD withBMC Medical Genetics 2008, 9:33 http://www.biomedcentral.com/1471-2350/9/33
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it). Last, we observed that levels of FAM5C change with
passage in AoSMC, implying that genetic variation in the
gene might be involved in AoSMC cellular processes
involved in the formation of unstable atherosclerotic
plaque leading to MI. Further work to elucidate the func-
tion of FAM5C in MI, including the MI-associated poly-
morphisms and its downstream targets, is necessary in
order to begin to understand the role this mitochondrial
molecule plays in this disease.
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